At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARVN Arvinas Holding Company LLC
Trading 08-04 12:58:10 EDT
9.61
+1.55
+19.23%
High9.65Low8.39Vol1.37M
Open8.45D1 Closing8.06Amplitude15.63%
Mkt Cap617.20MTradable Cap536.28MTotal Shares64.22M
T/O12.59MT/O Rate2.46%Tradable Shares55.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
MT Newswires Live  ·  08-04 23:41
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
Arvinas Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-04 21:31
Arvinas Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Arvinas Q2 Operating Income USD 164.1 Million
Reuters  ·  08-04 19:21
Arvinas Q2 Operating Income USD 164.1 Million
Arvinas Swings to FY26 Q2 Net Income of $169.4 Million; Revenue More than Doubled to $249.7 Million
Reuters  ·  08-04 19:06
Arvinas Swings to FY26 Q2 Net Income of $169.4 Million; Revenue More than Doubled to $249.7 Million
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate
Benzinga Earnings  ·  08-04 19:05
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate
Arvinas Q2 Operating Expenses USD 85.6 Million
THOMSON REUTERS  ·  08-04 19:00
Arvinas Q2 Operating Expenses USD 85.6 Million
Arvinas Q2 Net Income USD 169.4 Million
THOMSON REUTERS  ·  08-04 19:00
Arvinas Q2 Net Income USD 169.4 Million
Arvinas - Cash Position Expected to Fund Operations into Second Half of 2028
THOMSON REUTERS  ·  08-04 19:00
Arvinas - Cash Position Expected to Fund Operations into Second Half of 2028
Arvinas Shareholders Elect Two Directors at Annual Meeting
Reuters  ·  06-26
Arvinas Shareholders Elect Two Directors at Annual Meeting
Arvinas CMO Noah Berkowitz to depart July 3, company starts search for successor
Reuters  ·  06-23
Arvinas CMO Noah Berkowitz to depart July 3, company starts search for successor
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
Reuters  ·  06-18
Rigel Pharmaceuticals pays $70 million upfront for global rights to Arvinas-Pfizer breast cancer drug VEPPANU
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
TIPRANKS  ·  06-17
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Reuters  ·  06-17
BRIEF-Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing
THOMSON REUTERS  ·  06-17
Arvinas - Pfizer, and Rigel Receive Hsr Clearance for License Agreement on June 11, 2026 - SEC Filing
Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing
THOMSON REUTERS  ·  06-17
Arvinas - Co and Pfizer Eligible for up to $320 Mln in Milestone Payments and Tiered Royalties - SEC Filing
Rigel closes VEPPANU license deal, makes USD 70 million upfront payment
Reuters  ·  06-17
Rigel closes VEPPANU license deal, makes USD 70 million upfront payment
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
Reuters  ·  06-04
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease
THOMSON REUTERS  ·  06-04
Arvinas Joins the Michael J. Fox Foundation’s Lite and Ppmi Programs to Advance New Therapies Targeting Lrrk2 for Parkinson’s Disease
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Dow Jones  ·  06-03
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
TIPRANKS  ·  06-03
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

Introduction

Company Name.
Arvinas Holding Company LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Issue price:
--